172 Results for "

degradable kinases

" in MedChemExpress (MCE) Product Catalog:
Products (172)

172 Results for "degradable kinases" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-13822
CAS No.: 312636-16-1
Purity:  99.25%
Target:  

SphK Wnt Apoptosis

Research Areas:  

Cancer

SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-100932
CAS No.: 105637-50-1
Purity:  99.86%
Target:  

Myosin

Research Areas:  

Cancer

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-112155
CAS No.: 2229036-62-6
Purity:  99.72%
Research Areas:  

Cancer

MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19 nM for binding affinity to ALK .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-70006
CAS No.: 851983-85-2
Synonyms: TOK-001; VN-124-1
Galeterone (TOK-001) is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone also functions as a CYP17 inhibitor (IC50 = 47 nM). Galeterone induces cell apoptosis. Galeterone inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research [1][2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-141512
CAS No.: 2705844-82-0
Purity:  98.97%
Target:  

PROTACs Aurora Kinase

Research Areas:  

Cancer

JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132296
CAS No.: 2743427-26-9
Purity:  99.26%
Target:  

FAK PROTACs

Research Areas:  

Cancer

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112557
CAS No.: 2052306-13-3
Purity:  98.2%
Target:  

PROTACs IKK

Research Areas:  

Cancer

PROTAC TBK1 degrader-2 is a potent PROTAC degrader of serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC50=15 nM; Kd=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC50=8.7 nM), with low selectivity over TBK1 (IC50=1.3 nM) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-123919
CAS No.: 2229037-19-6
Purity:  98.15%
Research Areas:  

Cancer

TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib (HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-130665
CAS No.: 2250025-88-6
Purity:  99.63%
Target:  

PROTACs CDK

Research Areas:  

Cancer

TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC50=73 nM) and CDK9/cyclin T1 (IC50=55 nM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111866
CAS No.: 1801547-16-9
Purity:  99.89%
Target:  

PROTACs RIP kinase

Research Areas:  

Metabolic Disease

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112273
CAS No.: 1639009-81-6
Purity:  98.78%
Target:  

Aurora Kinase

Research Areas:  

Cancer

CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112273A
CAS No.: 2926498-81-7
Purity:  99.62%
Target:  

Aurora Kinase

Research Areas:  

Cancer

CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W157689
CAS No.: 49619-58-1
Target:  

Proteolytic Enzyme IDE

Research Areas:  

Infection Metabolic Disease Cancer

IDE-IN-2 (Compound 4) is an inhibitor for insulin-degrading enzyme. IDE-IN-2 is predicted to have CYP3A4, CYP2C19, hERG, NADP+, HIF1α and histidine kinase inhibitory activities, and has potential biological activity in anti-diabetic, anti-tumor, anti-bacterial aspects, according to the in silico prediction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-138779
CAS No.: 1803605-68-6
Purity:  99.25%
Research Areas:  

Inflammation/Immunology

ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153896
CAS No.: 2764850-23-7
Purity:  98.74%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

LMTK3-IN-1 (compound C28) is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM),that acts by degrading LMTK3 via the ubiquitin-proteasome pathway. LMTK3-IN-1 shows anticancer activity in a variety of cancer cell lines and in vivo BC mouse models. LMTK3-IN-1 induces apoptosis in BC cell lines at 10-20 μM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N6625
CAS No.: 1897-45-6
Chlorothalonil is a broad-spectrum foliar fungicide with oral activity. Chlorothalonil can be used to combat fungal diseases in vegetable and crop leaves. Chlorothalonil can alter the microbial community in the soil. Chlorothalonil inhibits spermatogenesis. Chlorothalonil can cause intestinal epithelial barrier dysfunction and fetal toxicity .
loading...
    loading...
Cat. No.: HY-175749
CAS No.: 3025467-07-3
Target:  

Molecular Glues Wee1

Research Areas:  

Inflammation/Immunology Cancer

BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader. BMS-986463 significantly inhibits tumor regression and reduces the level of phospho-CDK2. BMS-986463 can be used for advanced malignant solid tumors like non-small cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-137677B
CAS No.: 94825-44-2
Purity:  96.04%
Synonyms: Guanosine 5'-[γ-thio]triphosphate tetralithium
Target:  

GLUT

Research Areas:  

Metabolic Disease

GTPγS (Guanosine 5'-[γ-thio]triphosphate) tetralithium is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS tetralithium to couple with G- protein α, to study its effect on kinase activity. GTPγS tetralithium acts as a component of lysis buffer .
loading...
    loading...
Cat. No.: HY-141796
CAS No.: 2407452-77-9
Purity:  98.64%
Target:  

PROTACs WDR5

Research Areas:  

Cancer

MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects .
loading...
    loading...
Cat. No.: HY-148065
CAS No.: 2769753-07-1
Purity:  98.77%
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
loading...
    loading...